Wikiwand AI

Esreboxetine

Chemical compound From Wikipedia, the free encyclopedia

Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor. It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.[1][2]

Other namesAXS-14; PNU-165442G
Routes of
administrationOral
ATC code
  • None
Legal status
  • In general: uncontrolled
Quick facts Clinical data, Other names ...
Esreboxetine
Clinical data
Other namesAXS-14; PNU-165442G
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • (2S)-2-[(S)-(2-ethoxyphenoxy)phenyl
    methyl]morpholine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H23NO3
Molar mass313.397 g·mol−1
3D model (JSmol)
  • CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
  • InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 X markN
  • Key:CBQGYUDMJHNJBX-OALUTQOASA-N X markN
 X markNcheckY (what is this?)  (verify)
Close

Esreboxetine was developed by Pfizer for the treatment of neuropathic pain and fibromyalgia. It failed to show significant benefit over currently available medications and was discontinued.[1][3][4][5] A subsequent 2012 study (n=277) found esreboxetine gave significant reductions in pain and fatigue in fibromyalgia patients.[6]

References

Related Articles

Timelines

Top Qs

Fact Checks